0 569

Cited 91 times in

ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts

DC Field Value Language
dc.contributor.author강숙희-
dc.contributor.author김백길-
dc.contributor.author장연수-
dc.contributor.author조남훈-
dc.date.accessioned2020-02-11T06:43:59Z-
dc.date.available2020-02-11T06:43:59Z-
dc.date.issued2020-
dc.identifier.issn0950-9232-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/174821-
dc.description.abstractIntegrin beta 4 (ITGB4) overexpression in cancer cells contributes to cancer progression. However, the role of stromal ITGB4 expression in cancer progression remains poorly understood, despite stromal ITGB4 overexpression in malignant cancers. In our study, ITGB4-overexpressing triple negative breast cancer (TNBC) cells provided cancer-associated fibroblasts (CAFs) with ITGB4 proteins via exosomes, which induced BNIP3L-dependent mitophagy and lactate production in CAFs. In coculture assays, the ITGB4-induced mitophagy and glycolysis were suppressed in CAFs by knocking down ITGB4 or inhibiting exosome generation in MDA-MB-231, or blocking c-Jun or AMPK phosphorylation in CAFs. ITGB4-overexpressing CAF-conditioned medium promoted the proliferation, epithelial-to-mesenchymal transition, and invasion of breast cancer cells. In a co-transplant mouse model, MDA-MB-231 made a bigger tumor mass with CAFs than ITGB4 knockdown MDA-MB-231. Herein, we presented how TNBC-derived ITGB4 protein triggers glycolysis in CAFs via BNIP3L-dependent mitophagy and suggested the possibility that ITGB4-induced mitophagy could be targeted as a cancer therapy.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherNature Publishing Group-
dc.relation.isPartOfONCOGENE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학교실)-
dc.contributor.googleauthorJin Sol Sung-
dc.contributor.googleauthorChan Woo Kang-
dc.contributor.googleauthorSuki Kang-
dc.contributor.googleauthorYeonsue Jang-
dc.contributor.googleauthorYoung Chan Chae-
dc.contributor.googleauthorBaek Gil Kim-
dc.contributor.googleauthorNam Hoon Cho-
dc.identifier.doi10.1038/s41388-019-1014-0-
dc.contributor.localIdA00044-
dc.contributor.localIdA00484-
dc.contributor.localIdA03449-
dc.contributor.localIdA03812-
dc.relation.journalcodeJ02413-
dc.identifier.eissn1476-5594-
dc.identifier.pmid31534187-
dc.identifier.urlhttps://www.nature.com/articles/s41388-019-1014-0-
dc.contributor.alternativeNameKang, Suki-
dc.contributor.affiliatedAuthor강숙희-
dc.contributor.affiliatedAuthor김백길-
dc.contributor.affiliatedAuthor장연수-
dc.contributor.affiliatedAuthor조남훈-
dc.citation.volume39-
dc.citation.number3-
dc.citation.startPage664-
dc.citation.endPage676-
dc.identifier.bibliographicCitationONCOGENE, Vol.39(3) : 664-676, 2020-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.